Head and Neck Squamous Cell Carcinoma (HNSCC) Recruiting Phase 1 / 2 Trials for Cetuximab (DB00002)

Also known as: Head and Neck Squamous Cell Carcinoma

IndicationStatusPhase
DBCOND0043665 (Head and Neck Squamous Cell Carcinoma (HNSCC))Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03370276Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell CarcinomaTreatment
NCT02507154Reactivating NK Cells in Treating Refractory Head and Neck CancerTreatment